Reuters logo
BRIEF-Merck says triple therapy using Idenix hepatitis drug could speed cures, treat all genotypes
June 9, 2014 / 1:00 PM / 3 years ago

BRIEF-Merck says triple therapy using Idenix hepatitis drug could speed cures, treat all genotypes

June 9 (Reuters) - Merck & Co Inc : * Research chief says triple combination of Idenix nucleotide inhibibor

idx21437 and leading two experimental Merck drugs could produce cures in 4 to

6 weeks * Research chief says triple combination, using idx21437, has potential to

eliminate hepatitis c virus in all genotypes * Research chief says global company reach could bring triple combination to

countries most affected by genotypes 2 and 3, virus types less common in U.S. * Says its own experimental dual therapy of mk-5172 and mk-8742 cures ”high

nineties” percentage of patients in 12 weeks; says triple therapy could be

more effective, faster

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below